Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Rivaroxaban 15 mg	709
Overall Study	STARTED	Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)	709
Overall Study	STARTED	Vitamin K Antagonist (VKA)	706
Overall Study	Treated	Rivaroxaban 15 mg	696
Overall Study	Treated	Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)	706
Overall Study	Treated	Vitamin K Antagonist (VKA)	697
Overall Study	COMPLETED	Rivaroxaban 15 mg	550
Overall Study	COMPLETED	Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)	557
Overall Study	COMPLETED	Vitamin K Antagonist (VKA)	492
Overall Study	NOT COMPLETED	Rivaroxaban 15 mg	159
Overall Study	NOT COMPLETED	Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD)	152
Overall Study	NOT COMPLETED	Vitamin K Antagonist (VKA)	214

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01830543/flow